Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule

Medical Science Monitor

Volumn 15, Issue 4, 2009, Pages

  De Gennaro Colonna, Vito ^a   Bianchi, Mauro ^a   Pascale, Valerio ^a   Ferrario, Paolo ^a   Morelli, Franca ^a   Pascale, Walter ^a   Tomasoni, Livio ^a   Turiel, Maurizio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Asymmetric dimethylarginine (ADMA); Atherosclerosis; Cardiovascular risk; Coronary heart disease; Endothelial dysfunction; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOSARTAN; METFORMIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; PIOGLITAZONE; PRAVASTATIN; PROBUCOL; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA; ZOFENOPRIL;

AMINO ACID SYNTHESIS; ARTERY DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STABLE ANGINA PECTORIS; SYNDROME X;

ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; KIDNEY; NITRIC OXIDE SYNTHASE; RISK FACTORS;

EID: 65949106586     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Moncada S, Palmer R, Higgs E: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev, 1991; 43: 109-142
2. Moncada S, Higgs A: The l-arginine-nitric oxide pathway. N Engl J Med, 1993; 329: 2002-2012
3. Whittle BJ, Lopez-Belmonte J, Rees DD: Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol, 1989; 98: 646-652 (Pubitemid 19245774)
4. Ribeiro MO, Antunes E, Nicci G et al: Chronic inhibition of nitric oxide synthesis. A new model of hypertension. Hypertension, 1992; 20: 298-303
5. De Gennaro Colonna V, Rossoni G, Rigamonti A et al: Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol, 2002; 450: 61-66
6. Vallance P, Leone A, Calver A et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992; 339: 572-575
7. Furchgott RF, Zawadzski JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980; 288: 373-376
8. Ignarro LJ, Byrns RE, Buga GM et al: Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res, 1987; 61: 866-879
9. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 1987; 327: 524-526
10. Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 1988; 333: 664-666
11. Luscher TF, Noll G: Endothelial function as an end-point in interventional trials: concepts, methods and current data. J. Hypertens Suppl, 1996; 14: S111-21
12. Boo YC, Hwang J, Sykes M et al: Shear stress stimulates phosphorylation of eNOS at ser(635) by a protein kinase A-dependent mechanism. Am J Physiol Heart Circ Physiol, 2002; 283: H1819-28
13. Arnold WP, Mittal CK, Katsuki S et al: Nitric oxide activates guanylate cyclase and increases guanosine 3′: 5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA, 1977; 74: 3203-3207
14. Radomski M, Palmer R, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet, 1987; 2: 1057-1058
15. Radomski M, Palmer R, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA, 1990; 87: 5193-5197
16. Gryglewski RJ, Chlopicki S, Swies J et al: Prostacyclin, nitric oxide, and atherosclerosis. Ann NY Acad Sci, 1995; 748: 194-206
17. Cooke JP, Dzau VS: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med, 1997; 48: 489-509
18. De Caterina R, Libby P, Peng HB et al: Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest, 1995; 96: 67B-70B
19. Khan BV, Harrison DG, Olbrych MT et al: Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells: Proc Natl Acad Sci USA, 1996; 93: 9114-9119 (Pubitemid 26282027)
20. Garg U, Hassid A: Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest, 1989; 83: 1774-1777
21. Schwartz SM, Heimark RL, Majeski MW: Developmental mechanisms underlying pathology of arteries. Physiol Rev, 1990; 70: 1177-1209
22. Boger RH, Bode-Boger SM, Mugge A et al: Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis, 1995; 117: 273-284
23. Hogg N, Kalyanaraman B, Joseph J et al: Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett, 1993; 334: 170-174
24. G-dimethylarginine, and NG,NG-dimethylarginine in the rabbit. Biochem J, 1976; 154: 179-184
25. Ghosh SK, Paik WK, Kim S: Purification and molecular identification of two protein methylases I from calf brain: myelin basic protein- and histone-specific enzyme. J Biol Chem, 1988; 263: 19024-19033
26. Rawal N, Rajpurohit R, Paik WK, Kim S: Purification and characterization of S-adenosylmethionine-protein-arginine N-methyltransferase from rat liver. Biochem J, 1994; 300: 483-489
27. Leiper JM, Santa Maria J, Chubb A et al: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distribution and homology with microbial arginine deaminases. Biochem J, 1999; 343: 209-214
28. Murray-Rust J, Leiper J, McAlister M et al: Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol, 2001; 8: 679-683
29. Xiao S, Wagner L, Schmidt RJ, Baylis C: Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int, 2001; 59: 1466-1472
30. Leiper J, Mrray-Rust J, McDonald N, Vallance P: S-nitrosylation of dimethylargine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA, 2002; 99: 13527-13532
31. McAllister RJ, Parry H, Kimoto M et al: Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol, 1996; 1533-1540
32. Ito A, Tsao PS, Adimoolam S et al: Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation, 1999; 99: 3092-3095
33. Stuhlinger MC, Tsao PS, Her JH et al: Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation, 2001; 104: 2569-2575
34. Lin KY, Ito A, Asagami T et al: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation, 2002; 987-992
35. Gardiner SM, Kemp PA, Bennett T et al: Regional and cardiac haemodynamic effects of NG, NG dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol, 1993; 110: 1457-1464 (Pubitemid 23360978)
36. De Gennaro Colonna V, Bonomo S, Ferrario P et al: Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. Eur J Pharmacol, 2007; 557: 178-185
37. Kielstein JT, Impraim B, Simmel S et al: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation, 2004; 109: 172-177
38. Achan V, Broadhead M, Malaki M et al: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol, 2003; 23: 1455-1459
39. Kielstein JT, Simmel S, Bode-Boger SM et al: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res, 2004; 27: 143-147
40. Kielstein JT, Donnerstag F, Gasper S et al: ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke, 2006; 37: 2024-2029
41. MacAllister RJ, Rambausek MH, Vallance P et al: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant, 1996; 11: 2449-2452
42. Kielstein JT, Boger RH, Bode-Boger SM et al: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol, 1999; 10: 594-600
43. Schmidt RJ, Yokota S, Tracy TS et al: Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol, 1999; 276: F794-97
44. Kielstein JT, Boger RH, Bode-Boger SM et al: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol, 2002; 13: 170-176
45. Fliser D, Kielstein JT, Haller H, Bode-Boger SM: Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int Suppl, 2003; 84: S37-40 (Pubitemid 36513371)
46. Fliser D, Kronenberg F, Kielstein JT et al: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol, 2005; 16: 2456-2461
47. Lindner A, Charra B, Sherrad D, Scribner BH: Accelerated atherosclerosis in prolonged maintenance. N Engl J Med, 1974; 290: 697-701
48. London GM, Drueke TB: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int, 1997; 51: 1678-1695
49. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet, 2000; 356: 147-152
50. Zoccali C, Bode-Boger S, Mallamaci F et al: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet, 2001; 358: 2113-2117
51. Ravani P, Tripepi G, Malberti F et al: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol, 2005; 16: 2449-2455
52. Miyazaki H, Matsuoka H, Cooke JP: Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation, 1999; 99: 1141-1146
53. Kielstein JT, Bode-Boger SM, Frolich JC et al: Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation, 2003; 107: 1891-1895 (Pubitemid 36444130)
54. Boger RH, Bode-Boger SM, Thiele W et al: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation, 1997; 95: 2068-2074
55. Boger RH, Bode-Boger SM, Thiele W et al: Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol, 1998; 32: 1336-1344
56. Boger RH, Bode-Boger SM, Szuba A et al: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998; 98: 1842-1847
57. Lundman P, Eriksson MJ, Stuhlinger M et al: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol, 2001; 38: 111-116
58. Fard A, Tuck CH, Donis JA et al: Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol, 2000; 20: 2039-2044
59. Abbasi F, Asagmi T, Cooke JP et al: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol, 2001; 88: 1201-1203
60. Stuhlinger MC, Abbasi F, Chu JW et al: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002; 287: 1420-1426
61. Petrie JR, Ueda S, Webb DJ et al: Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation, 1996; 93: 1331-1333
62. Steinberg HO, Chaker H, Leaming R et al: Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest, 1996; 97: 2601-2610
63. Yasuda S, Miyazaki S, Kanda M et al: Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J, 2006; 27: 1159-1165
64. Morohoshi M, Fujisawa K, Uchimura I, Numano F: Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes, 1996; 45: 954-959 (Pubitemid 26225513)
65. Surdacki A, Nowicki M, Sandmann J et al: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol, 1999; 652-658
66. Goonasekera CDA, Rees DD, Woolard P et al: Nitric oxide synthase inhibitors in children and adolescents. J Hypertens, 1997; 15: 901-909
67. Paiva H, Laakso J, Laine H et al: Plasma asymmetric dimethylarginine and hyperaemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol, 2002; 40: 1241-1247
68. Takiuchi S, Fujii H, Kamide K et al: Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens, 2004; 17: 802-808
69. Valkonen VP, Paiva H, Salonen JT et al: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet, 2001; 358: 2127-2128
70. Lu TM, Ding YA, Lin SJ et al: Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J, 2003; 24: 1912-1919
71. Krempl TK, Maas R, Sydow K et al: Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J, 2005; 26: 1846-1851
72. Schnabel R, Blankenberg S, Lubos E et al: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res, 2005; 97: e53-59
73. Meinitzer A, Seelhorst U, Wellnitz B et al: Asymmetric dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem, 2007; 53: 273-283
74. Mittermayer F, Krzyzanowska K, Exner M et al: Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol, 2006; 26: 2536-2540
75. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G: Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care, 2007; 30: 1834-1839
76. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998; 97: 1129-1135
77. Corsini A, Pazzucconi F, Arnaboldi L et al: Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol, 1998; 31: 773-778
78. Bustos C, Herǹndez-Presa MA, Ortego M et al: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 1998; 32: 2057-2064
79. Bellosta S, Via D, Canavesi M et al: HMG-CoA reductase inhibitors reduce MM-9 secretion by macrophages. Arterioscler Thromb Vasc Biol, 1998; 18: 1671-1678
80. Hussein O, Rosenblat M, Schlezinger S et al: Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol, 1997; 44: 77-83
81. Eid HM, Eritsland J, Larsen J et al: Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis, 2003; 166: 279-284
82. Paiva H, Laakso J, Lehtimaki T et al: Effect of a high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol, 2003; 41: 219-222
83. Valkonen VP, Laakso J, Paiva H et al: Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl, 2003; 4: 19-22
84. Shinohara K, Shoji T, Kimoto E et al: Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2005; 12: 205-210
85. Lu TM, Ding YA, Leu HB et al: Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol, 2004; 94: 157-161
86. Kersten S, Desvergue B, Wahli W: Roles of PPARs in health and disease. Nature, 2000; 405: 421-424
87. Dierkes J, Westphal S, Martens-Lobenhoffer J, Luley C, Bode-Boger SM: Fenofibrate increases the L-arginine: ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. Atherosclerosis, 2004; 173: 239-244
88. Yang TL, Chen MF, Xia X et al: Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. Eur J Clin Pharmacol, 2006; 62: 179-184
89. Yang TL, Chen MF, Luo BL et al: Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schiedeberg's Arch Pharmacol, 2004; 370: 79-83
90. Petrofsky JS, Lee S: The impact of rosiglitazone on cardiovascular responses and endurance during isometric exercise in patients with Type 2 Diabetes. Med Sci Monit, 2006; 12(1): CR21-26
91. Wang TD, Chen WJ, Cheng WC et al: Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol, 2006; 98: 1057-1062 (Pubitemid 44486144)
92. Bailey CJ: Biguanides and NIDDM. Diabetes Care, 1992; 15: 755-772
93. Asagami T, Abbasi F, Stuehlinger M et al: Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism, 2002; 51: 843-846
94. Chen JW, Hsu NW, Wu TC et al: Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol, 2002; 90: 974-982
95. Delles C, Schneider MP, John S et al: Angiotensin converting enzyme inhibition and angiotensin II AT-1-receptor blockade reduce the levels of asymmetrical NG, NG-dimethylarginine in human essential hypertension. Am J Hypertens, 2002; 15: 590-593 (Pubitemid 34734805)
96. Ito A, Egashira K, Narishige T et al: Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J, 2001; 65: 775-778
97. Ito A, Egashira K, Narishige T et al: Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J, 2002; 66: 811-815
98. Hayek T, Attias J, Coleman R et al: The angiotensin-converting enzyme inhibitor fosinopril and the angiotensin II receptor antagonist losartan inhibit LDL oxidation, and attenuate atherosclerosis independent of lowering blood pressure, in apolipoprotein E deficient mice. Cardiovasc Res, 1999; 44: 579-587 (Pubitemid 30012061)
99. Hayek T, Kaplan M, Raz A et al: Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis, 2002; 161: 65-74
100. Napoli C, Sica V, de Nigris F et al: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J, 2004; 148: e5
101. Engler MM, Engler MB, Malloy MJ et al: Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation, 2003; 108: 1059-1063
102. Saran R, Novak JE, Desai A et al: Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Trasplant, 2003; 18: 2415-2420
103. Jiang JL, Li NS, Li YJ, Deng HW: Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol, 2002; 135: 1175-1182
104. Tagawa T, Urabe Y, Kimura Y et al: Long-term treatment with probucol improves endothelial function in patients with coronary artery disease. Hypertens Res, 2004; 27: 311-318
105. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PAM: Determination of arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem, 2002; 303: 131-137 (Pubitemid 34407576)
106. Vishwanathan K, Tackett RL, Stewart JT, Bartlett MG: Determination of arginine and methylated arginines in human plasma by liquid chromatography- tandem spectrometry. J Chromatogr, 2000; 748: 157-166
107. Schulze F, Wesemann R, Schwedhelm E et al: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med, 2004; 42: 1377-1383